Kezdőlap・Részvénylista・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Lezárt

SzektorEgészségügy

3.2 2.24

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

3.12

Maximum

3.25

Fő mutatók
By Trading Economics
Bevétel	4.1M -5.7M
Egy részvényre jutó nyereség	-0.06
Munkavállalók	34
EBITDA	-821K -6.5M

Osztalékok
By Acuity
Következő eredményjelentés	2026. aug. 11.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	42M 273M
Előző nyitás	0.96
Előző zárás	3.2

Hangulat hírek alapján

By Acuity

50%

156 / 340 Rangsor szerint Healthcare

Anavex Life Sciences Corp Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 5. 21:01 UTC

Anavex Life Sciences shares fell in after-market trading, declining significantly despite being above its 20-day moving average and near the top of its one-month range.

2026. aug. 4. 19:51 UTC

Anavex Life Sciences Corp is rising amid broader market strength and a decline in crude oil prices, despite pulling back from earlier session highs.

2026. aug. 3. 20:02 UTC

News

Anavex Life Sciences Corp announces board changes amid a proxy fight, urging stockholders to reject PVG Asset Management's attempt to replace the board. Shares are higher.

2026. júl. 30. 19:39 UTC

Event

Anavex Life Sciences reported Q2 earnings of -$0.06 per share, beating expectations. Shares remain higher since Wednesday's close despite pulling back from session highs.

2026. júl. 29. 22:31 UTC

Anavex Life Sciences Corp shares are higher in after-market trading, reflecting broader market gains following the Federal Reserve's decision to maintain interest rates.

2026. júl. 28. 21:01 UTC

Anavex Life Sciences Corp shares are lower in after-market hours, currently 1.45% below their 20-day moving average. No specific news was identified.

2026. júl. 27. 20:07 UTC

Anavex Life Sciences Corp shares are higher during Monday's session, maintaining gains since Friday amid broader market trends and easing geopolitical tensions.

2026. júl. 24. 17:46 UTC

Anavex Life Sciences Corp shares are lower today, continuing a decline since Thursday's close, with no specific news identified to explain the move.

2026. júl. 21. 19:51 UTC

Anavex Life Sciences is rising during Tuesday's session, recovering from a pre-market low. Broader market sentiment is supported by positive earnings from General Motors and Novartis.

Társak összehasonlítása

Árváltozás

Anavex Life Sciences Corp Előrejelzés

Értékelési konszenzus

By TipRanks

0 ratings

Vétel

Tartás

Eladás

0 Wall Street elemző célárain alapulva a(z)Anavex Life Sciences Corp termékhez az elmúlt 3 hónapban.

Hangulat

By Acuity

156 / 340 Rangsor szerint Egészségügy

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.